NeuroSense Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
NeuroSense Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on advancing therapies for ALS and other central nervous system disorders. It is developing PrimeC as a treatment candidate and is conducting a Phase 2b, double-blind, randomized, placebo-controlled study in ALS patients globally. The company's work centers on research and development for neurodegenerative diseases, with ALS as a primary program. Positioned within the biotechnology research sector, it pursues therapeutic development for challenging CNS indications. The company is publicly traded on NASDAQ under the ticker NRSN. In 2026, NeuroSense announced plans to initiate Phase 3 development of PrimeC after patent awards in Japan, Brazil, Australia and the United States, expanding its global intellectual property portfolio. The organization is described as a small-to-mid-sized firm dedicated to clinical research.
1-888-653-2347 
support@leadiq.com 
